BOCA RATON, Fla., Jan. 3, 2017 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions such as keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, CEO and Arthur Levine, CFO will participate in the Annual JP Morgan Healthcare Conference Week to be held in San Francisco on Monday, January 9th through Wednesday, January 11th.
Management will be meeting with new and existing analysts, investors and customers at the Kensington Park Hotel nearby the conference. Those interested in scheduling a one-on-one meeting with management should contact investor relations at sensus@kcsa.com.
About Sensus
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://sensushealthcare.com.
Investor Relations:
Jeffrey Goldberger / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1249 / 212-896-1267
Email: jgoldberger@kcsa.com / asoss@kcsa.com
To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/sensus-healthcare-to-participate-in-annual-jp-morgan-healthcare-conference-week-on-january-9th–11th-in-san-francisco-300382722.html
SOURCE Sensus Healthcare, Inc.